Interpretation of the 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of Kawasaki disease

The 2021 American College of Rheumatology/Vasculitis Foundation guidelines for the management of Kawasaki disease (KD) provided evidence-based recommendations and expert guidance for the treatment of KD, with a focus on clinical situations more commonly handled by rheumatologists. The good practice...

Full description

Saved in:
Bibliographic Details
Main Authors: PAN Yan, YAN Xiaohua, KUO Hochang, DING Yan, JIAO Fuyong
Format: Article
Language:zho
Published: Editorial Office of New Medicine 2024-11-01
Series:Yixue xinzhi zazhi
Subjects:
Online Access:https://yxxz.whuznhmedj.com/futureApi/storage/attach/2412/Dm8B5RK1fJ82bgOwJG57u9ez3FGqJG6h6RUDs2ts.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The 2021 American College of Rheumatology/Vasculitis Foundation guidelines for the management of Kawasaki disease (KD) provided evidence-based recommendations and expert guidance for the treatment of KD, with a focus on clinical situations more commonly handled by rheumatologists. The good practice statement confirmed that all KD patients should receive initial treatment with intravenous immunoglobulin (IVIg). Additionally, the guideline included 7 strong recommendations and 4 conditional recommendations for the treatment of KD or suspected KD.The strong recommendations emphasized the timely treatment of incomplete KD, the use of aspirin therapy, and the performance of echocardiography in cases of macrophage activation syndrome or shock of unknown origin. The conditional recommendations suggested the use of IVIg and other adjunctive therapies for patients with KD who were resistant to IVIg and/or had high-risk features for coronary artery aneurysms. This guideline provided direction on diagnostic strategies, drug selection, and the use of echocardiography for suspected or confirmed KD patients. This article referenced both domestic and international literature to interpret the key points of the guideline, aiming to provide useful insights for pediatricians in China.
ISSN:1004-5511